Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM) Short Interest Down 4.4% in April

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) saw a large drop in short interest in the month of April. As of April 30th, there was short interest totalling 944,959 shares, a drop of 4.4% from the April 15th total of 987,974 shares. Based on an average daily volume of 312,700 shares, the short-interest ratio is presently 3.0 days. Currently, 2.1% of the shares of the company are short sold.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. increased its position in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 9.4% in the 3rd quarter. BlackRock Inc. now owns 1,727,098 shares of the company’s stock valued at $3,230,000 after acquiring an additional 147,828 shares during the period. Vanguard Group Inc increased its position in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 6.1% in the 3rd quarter. Vanguard Group Inc now owns 145,747 shares of the company’s stock valued at $273,000 after acquiring an additional 8,381 shares during the period. Rhumbline Advisers increased its position in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 56.5% in the 4th quarter. Rhumbline Advisers now owns 46,410 shares of the company’s stock valued at $57,000 after acquiring an additional 16,750 shares during the period. Finally, Geode Capital Management LLC grew its position in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 13.3% during the 4th quarter. Geode Capital Management LLC now owns 136,655 shares of the company’s stock worth $168,000 after purchasing an additional 16,065 shares during the period. 14.63% of the stock is currently owned by institutional investors.

Shares of ZOM opened at $0.30 on Thursday. Zomedica Pharmaceuticals Corp has a fifty-two week low of $0.26 and a fifty-two week high of $2.98.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) last announced its quarterly earnings results on Friday, May 10th. The company reported ($0.12) earnings per share for the quarter.

COPYRIGHT VIOLATION NOTICE: This report was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/23/zomedica-pharmaceuticals-corp-nyseamerican-zom-short-interest-down-4-4-in-april.html.

About Zomedica Pharmaceuticals Corp (NYSEAMERICAN)

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.

Recommended Story: Bollinger Bands

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.